Novo Nordisk– tag –
-
Rani Therapeutics Achieves 84% Bioavailability for Oral Ustekinumab Biosimilar; Oral GLP-1s Drive Commercial Success in Biopharma Delivery
Drug Delivery Leader USA Overview The successful FDA approval and commercial launch of oral semaglutide (Wegovy) and orforglipron highlight the critical role of oral delivery in chronic disease management, significantly improving patient... -
Oral GLP-1 Receptor Agonists Foundayo (Orforglipron) and Wegovy Pill (Oral Semaglutide) Demonstrate Average Weight Loss of 12.4% and 16.6% Respectively by 2026
PrivateDoc® Unknown Overview By 2026, two oral GLP-1 receptor agonists, Foundayo (orforglipron) and Wegovy pill (oral semaglutide), are approved for weight management in the UK. Foundayo, a small-molecule non-peptide, can be taken with o... -
Insilico Medicine’s AI-Designed Drug Rentosertib Shows Early Signs of Biological Age Reversal, Enters Phase III for Idiopathic Pulmonary Fibrosis
Inc.com USA Overview Insilico Medicine's AI-generated small molecule, rentosertib, has demonstrated early signs of reducing six protein-based biological age markers by an average of 10.3% in a 12-week clinical trial. This breakthrough ma... -
Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline
Becker's Hospital Review Unknown Overview A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics' oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction i... -
Upside Foods Withdraws $50M Bid for Believer Meats’ US Facility, Signaling Strategic Re-evaluation Amidst Industry Consolidation
AgFunderNews USA Overview US cultivated meat startup Upside Foods has withdrawn its $50 million bid to acquire the shuttered North Carolina facility of former competitor Believer Meats, yet confirmed its continued interest. The facility ... -
Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech for Accelerated Custom Luminescent Assay Development
The Scientist Global Overview AI-driven protein design company Monod Bio has entered into a non-exclusive licensing agreement with SignalChem Biotech, enabling the integration of Monod Bio's LuxSit de novo luciferase technology and NovoB... -
Biologics CDMO Market to Reach $38.29 Billion by 2031, Fill-Finish Emerging as Key Segment
GlobeNewswire Global Overview This article provides an overview of a market research report from GlobeNewswire. The Biologics CDMO market is projected to grow from $27.13 billion in 2026 to $38.29 billion by 2031, exhibiting a CAGR of 7.... -
FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine
Drugs.com USA Overview In August 2026, the FDA approved several key new drugs. Novo Nordisk's Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for ... -
Insilico Medicine Nominates ISM9077, Potential First-in-Class AI-Designed Target Y Inhibitor, as Preclinical Candidate for Ocular, Inflammatory, and Aging Disorders
Barchart.com (Insilico Medicine Press Release) Hong Kong Overview Insilico Medicine nominated ISM9077, a potential first-in-class Target Y inhibitor, as a preclinical candidate (PCC) for ocular diseases, inflammatory disorders, and aging... -
Oral GLP-1 Market Soars: Eli Lilly’s Foundayo and Novo Nordisk’s Oral Wegovy Reach New Prescription Highs
Fierce Pharma USA Overview Weekly prescriptions for Eli Lilly's oral GLP-1 agonist Foundayo and Novo Nordisk's oral Wegovy have reached new highs, demonstrating the significant impact of oral GLP-1 drugs on the obesity treatment landscap...
